DSpace Repository

COVID-19 in hematopoietic cell transplant recipients

Show simple item record

dc.contributor.author Altuntas, F
dc.contributor.author Ata, N
dc.contributor.author Yigenoglu, TN
dc.contributor.author Basci, S
dc.contributor.author Dal, MS
dc.contributor.author Korkmaz, S
dc.contributor.author Namdaroglu, S
dc.contributor.author Basturk, A
dc.contributor.author Hacibekiroglu, T
dc.contributor.author Dogu, MH
dc.contributor.author Berber, I
dc.contributor.author Dal, K
dc.contributor.author Erkurt, MA
dc.contributor.author Turgut, B
dc.contributor.author Ulgu, MM
dc.contributor.author Celik, O
dc.contributor.author Akunal, A
dc.contributor.author Birinci, S
dc.date.accessioned 2022-10-05T13:20:13Z
dc.date.available 2022-10-05T13:20:13Z
dc.date.issued 2021
dc.identifier.uri http://hdl.handle.net/11616/62730
dc.description.abstract In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.
dc.description.abstract C1 [Altuntas, Fevzi; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Hematol, Ankara, Turkey.
dc.description.abstract [Altuntas, Fevzi; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Bone Marrow Transplantat Ctr, Ankara, Turkey.
dc.description.abstract [Altuntas, Fevzi] Yildirim Beyazit Univ, Dept Internal Med, Div Hematol, Ankara, Turkey.
dc.description.abstract [Ata, Naim] Minist Hlth, Dept Strategy Dev, Ankara, Turkey.
dc.description.abstract [Korkmaz, Serdal] Univ Hlth Sci, Kayseri Training & Res Hosp, Dept Hematol, Kayseri, Turkey.
dc.description.abstract [Namdaroglu, Sinem] Univ Hlth Sci, Bozyaka Training & Res Hosp, Dept Hematol, Izmir, Turkey.
dc.description.abstract [Basturk, Abdulkadir] Selcuk Univ, Sch Med, Dept Internal Med, Div Hematol, Konya, Turkey.
dc.description.abstract [Hacibekiroglu, Tuba] Sakarya Univ, Sch Med, Dept Internal Med, Div Hematol, Sakarya, Turkey.
dc.description.abstract [Dogu, Mehmet Hilmi] Istanbul Training & Res Hosp, Dept Hematol, Istanbul, Turkey.
dc.description.abstract [Berber, Ilhami; Erkurt, Mehmet Ali] Inonu Univ, Sch Med, Dept Internal Med, Div Hematol, Malatya, Turkey.
dc.description.abstract [Dal, Kursat] Kecioren Training & Res Hosp, Dept Internal Med, Ankara, Turkey.
dc.description.abstract [Turgut, Burhan] Namik Kemal Univ, Sch Med, Dept Internal Med, Div Hematol, Tekirdag, Turkey.
dc.description.abstract [Ulgu, Mustafa Mahir; Akunal, Abdullah] Minist Hlth, Gen Directorate Hlth Informat Syst, Ankara, Turkey.
dc.description.abstract [Celik, Osman] Minist Hlth, Publ Hosp Gen Directorate, Ankara, Turkey.
dc.description.abstract [Birinci, Suayip] Hlth, Ankara, Turkey.
dc.source BONE MARROW TRANSPLANTATION
dc.title COVID-19 in hematopoietic cell transplant recipients


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record